HealthEquity shares fell 10.2% after management’s 2027 guidance failed to meet heightened investor expectations. Analysts had anticipated more aggressive top-line targets given the company’s track record of consistent revenue growth and margin expansion. Despite a robust Q4 performance, the market focused on the mid‐point of the revenue range, interpreting it as a cautious stance rather than a signal of underlying weakness in the business model.

HealthEquity’s health savings account (HSA) platform continues to demonstrate strength, with account growth reaching over 17 million consumer-directed benefit accounts and HSA assets under management exceeding $34 billion. In the latest quarter, HSA contributions climbed by 18% year-over-year, driving net new asset inflows of more than $2.5 billion. Fee revenue from asset balances accounted for 42% of total revenues, underscoring the importance of ongoing asset accumulation to the company’s financial profile.

Management projects full‐year 2027 revenue of $1.38–$1.41 billion, reflecting a compound annual growth rate of approximately 12% from 2023 levels. EBITDA margins are expected in the range of 43.8–44.3%, supported by operating leverage from the scalable SaaS platform and disciplined cost management initiatives. The company plans to invest in digital engagement tools and platform integrations to boost member activation rates and cross-sell opportunities, targeting an average HSA account balance increase of 5% annually through 2027.